LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on RAPT stock, giving a Buy rating on September 30.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sam Slutsky has given his Buy rating due to a combination of factors including the anticipation of significant upcoming catalysts for RAPT Therapeutics. The company is on the verge of releasing Phase 2 data for its anti-IgE therapy, JYB1904/RPT904, in collaboration with its Chinese partner, Jemincare. These data releases, expected later this year, will focus on chronic spontaneous urticaria and asthma, and are crucial as they aim to demonstrate clinical potential against a well-established treatment, omalizumab, with the added benefit of an improved dosing schedule.
Additionally, insights from a recent dinner with RAPT’s management team have reinforced the positive outlook. Investor sentiment and options market activity suggest a potential 30-40% increase in RAPT’s stock value following positive trial results. This optimism is further supported by the large market opportunity in food allergy, where RAPT is planning to initiate a Phase 2 study, indicating long-term growth potential for the company.
In another report released on September 30, Clear Street also maintained a Buy rating on the stock with a $41.00 price target.